News
Record numbers of women are freezing their eggs, data shows
Egg and embryo freezing cycles are the fastest growing treatments in the UK
More people than ever before are having fertility treatment as new data shows a 64 per cent increase in egg freezing and fertility preservation cycles.
The Fertility Treatment 2021: Preliminary Trends and Figures report, published by the Human Fertilisation & Embryology Authority (HFEA), has shown that around 55,000 patients had IVF or donor insemination treatment at UK licensed fertility clinics in 2021, compared to 53,000 in 2019.
The data has found that 83,000 IVF and donor insemination cycles were carried out in 2021 compared to 76,000 in 2019.
It has also revealed record numbers of patients are freezing their eggs for future use with 4,000 in 2021 compared to around 2,500 in 2019 (a 64 per cent rise).
The report, which shows how many patients undergo fertility treatment each year in UK fertility clinics, the type of treatment they have and the success rate, also shows the average pregnancy rate from IVF.
It suggests pregnancy rates using fresh embryo transfers have increased, rising to 29 per cent per embryo transferred in 2021 from 10 per cent in 1991.
“Overall, the new HFEA report paints a promising picture,” says Julia Chain, chair of the Human Fertilisation & Embryology Authority (HFEA).
“It shows treatment numbers are back at pre pandemic levels and thanks to improved clinical and laboratory practice, over time pregnancy rates are increasing.
“Despite the pandemic being declared officially over, the aftershocks are still being felt as delays across other areas of healthcare prevent some patients accessing fertility services.
“Our report shows that the average age of IVF patients has increased to 36, around five years older than mothers who get pregnant naturally and these aftershocks could mean that the average age of an IVF patient continues to rise.
“Although pregnancy rates have increased, the likelihood of success decreases with age. For some patients, this may mean they never get the baby they hoped for and that’s heart breaking.”
The Fertility Treatment 2021: Preliminary Trends and Figures report also shows:
- IVF cycles increased to 76,000 cycles in 2021 from almost 70,000 in 2019
- There were 11 times more egg freeze cycles in 2021 than in 2011; 373 cycles in 2011 compared to 4,215 cycles in 2021. The number of embryo freeze cycles increased from 230 cycles in 2011 to 10,719 in 2021.
- In 2021, the average IVF pregnancy rate using fresh embryo transfers for patients aged 18-34 was 41 per cent per embryo transferred with a birth rate of 33 per cent. This compares to six per cent for patients aged 43-50 when using their own eggs and a birth rate of four per cent.
- Single patients and patients in female same-sex relationships had the largest increase in IVF usage from 2019 to 2021.
- The use of private funding by patients across the UK aged 18-34 has continued to increase with 63 per cent of IVF cycles funded privately in 2021 compared to 52 per cent in 2019.
- The number of IVF cycles funded by the NHS continued to vary across the UK with an overall decrease to 20,000 cycles in 2021 from around 24,000 in 2019 (-16 per cent).
The fertility sector is a unique area of healthcare in the UK as the majority of patients pay for treatment themselves.
The proportion of NHS funded cycles have decreased right across the UK between 2019 and 2021, with data showing a 17 per cent reduction of NHS funded IVF cycles in England, 36 per cent in Wales and one per cent in Scotland.
“There were just under 4,000 fewer IVF cycles funded through the NHS between 2019 and 2021 so although more people than ever are having fertility treatment, our data shows that more people than ever are now also paying for it,” explains Chain.
“There could be several reasons why NHS funded cycles lag behind those seen before the pandemic.
“Firstly, we’ve seen a change in the type of family accessing fertility treatment with clinics treating 44 per cent more single patients and 33 per cent more patients in same sex female couples in 2021 than they did in 2019.
“Secondly, funding criteria varies depending on where you live and under current rules, very few single and same sex patients qualify for NHS funding,” she continues.
“And finally, measures put in place during the Covid-19 pandemic saw clinics prioritise older patients and this combined with waiting list backlogs elsewhere in the NHS, could mean that women are no longer eligible for NHS funding by the time they are referred for fertility treatment.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






